

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

OMB APPROVAL

OMB Number: 3235-0076

Expires: August 31, 2015

Estimated Average burden hours per response: 4.0

1. Issuer's Identity			
CIK (Filer ID Number)	Previous Name(s)	None	Entity Type
0001321834	Akers Bioscience	es Inc	• Corporation
Name of Issuer			C Limited Partnership
Akers Biosciences, Inc.			C
Jurisdiction of			Limited Liability Company
Incorporation/Organization	$\neg$		General Partnership
NEW JERSEY	<u></u>		C Business Trust
Year of Incorporation/Organiza	tion		C Other
Over Five Years Ago     Within Last Five Years			
O Within Last Five Years (Specify Year)			
C Yet to Be Formed			
2. Principal Place of	Business and	Contact Int	formation
Name of Issuer			
Akers Biosciences, Inc.			
Street Address 1		Street Address 2	
201 GROVE ROAD			
City	State/Province/Country	y ZIP/Postal	Code Phone No. of Issuer
THOROFARE	NEW JERSEY	08086	(856) 848-8698
0.0.1.1.0			
3. Related Persons			
Last Name	First Name		Middle Name
Yeaton	Howard		]
		St 1 1 1 2	
Street Address 1		Street Address 2	
201 Grove Road			
City	State/Province/Cou	intry	ZIP/Postal Code
Thorofare	NEW JERSEY		08086
Relationship: Exc	ecutive Officer	Director	Promoter
Clarification of Response (if Necess	sary)		
Interim Chief Financial Officer			
Last Name	First Name		Middle Name
Schreiber	Christopher		C.
Street Address 1	<u> </u>	Street Address 2	<u></u>
201 Grove Road			
City	State/Province/Cou	intry	ZIP/Postal Code

NEW JERSEY

Executive Officer

□ Director

08086

☐ Promoter

Thorofare

Relationship:

Clarification of Respon	se (if Necessary)			
Executive Chairman	f the Board of Directors; Princip	pal Executive Officer		
				-
Last Name	First Name		Middle Name	
Silverman	Joshua			
Street Address 1		Street Address 2		
201 Grove Road				
City	State/Province/O	Country	ZIP/Postal Code	
Thorofare	NEW JERSEY	Y	08086	
Relationship:	Executive Officer	Director	Promoter	
Clarification of Respon	se (if Necessary)			
				_
Last Name	First Name		Middle Name	
White	Bill		J.	
Street Address 1		Street Address 2		_
201 Grove Road				
City	State/Province/C	Country	ZIP/Postal Code	
Thorofare	NEW JERSEY	Y	08086	
Relationship:	Executive Officer	Director	Promoter	
Clarification of Respon	se (if Necessary)			
				_
Last Name	First Name		Middle Name	
Schroeder	Robert		C.	
Street Address 1		Street Address 2		
201 Grove Road				
City	State/Province/0	Country	ZIP/Postal Code	
Thorofare	NEW JERSEY	Y	08086	
Relationship:	Executive Officer	Director	Promoter	

# 4. Industry Group

Clarification of Response (if Necessary)

C Agriculture	Health Care	C Retailing
Banking & Financial Services	C Biotechnology	C Restaurants
C Commercial Banking	C Health Insurance C Hospitals & Physicians	
C Insurance	C Pharmaceuticals	Technology
C Investing	Other Health Care	C Computers
C Investment Banking		C Telecommunications
C Pooled Investment Fund		C Other Technology
Other Banking & Financial C Services		Travel
C Business Services	Manufacturing Real Estate	C Airlines & Airports
Energy	C Commercial	C Lodging & Conventions
C Coal Mining	C Construction	C Tourism & Travel Services
C Electric Utilities	C REITS & Finance	C Other Travel
© Energy Conservation © Environmental Services	C Residential	C Other
C Oil & Gas	Other Real Estate	
C Other Energy		
5 1 0:		
5. Issuer Size		
Revenue Range  No Revenues	Aggregate Net Asset  No Aggregate	_
7.40		e Net Asset Value
n=1	N=0	
0.40	140	
\$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000	( )	· \$100,000,000
Over \$100,000,000	Over \$100,00	
Decline to Disclose	C Decline to Di	
n=0	70 <u>—</u> 0	
C Not Applicable	C Not Applicab	ne
<ol><li>Federal Exemption(s) a apply)</li></ol>	nd Exclusion(s) Clain	ned (select all that
Rule 504(b)(1) (not (i), (ii)	Rule 505	
Rule 504 (b)(1)(i)	Rule 506(b)	
Rule 504 (b)(1)(ii)	Rule 506(c)	
Rule 504 (b)(1)(iii)	Securities Act Section 4(a)(5)	
	Investment Company Act Sec	tion 3(c)
7. Type of Filing		
New Notice Date of First Sale	2020-04-08	First Sale Yet to Occur
_	2020 01 00	
Amendment		
8. Duration of Offering		
		O Yes 6 No
Does the Issuer intend this offering to last mo	ore than one year?	Yes No
9. Type(s) of Securities Of	fered (select all that a	apply)
Pooled Investment Fund	quity	77
Interests		
☐ Tenant-in-Common Securities ☐ D	ebt	

☐ Mineral Property Securities ☐ Option, Warrant or Other Right to Acquire Another Security
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security  Other (describe)
10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
Clarification of Response (if Necessary)
11. Minimum Investment  Minimum investment accepted from any outside
investor \$ 0
12. Sales Compensation
Recipient Recipient CRD Number None
(Associated) Broker or Dealer None (Associated) Broker or Dealer CRD Number
Street Address 1 Street Address 2
City State/Province/Country ZIP/Postal Code
State(s) of Solicitation
12 Offering and Salas Amounts
13. Offering and Sales Amounts
Total Offering Amount \$ 459998 USD ☐ Indefinite
Total Amount Sold \$ 459998 USD
Total Remaining to be \$ 0 USD ☐ Indefinite
Clarification of Response (if Necessary)
Represents the issuance to the placement agent of warrants to purchase up to 61,333 shares of common stock at an exercise price
of \$7.50/share in connection with a registered offering of common stock that closed on April 8, 2020.
14. Investors
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,  Number of such non-accredited investors who already have invested in the offering
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

# 15. Sales Commissions & Finders' Fees Expenses

Sales Commissions	\$	0	USD	Estima	te
Finders' Fees	\$	0	USD	<b>Estima</b>	te
Clarification of Response (if Necessar	ry)				
16. Use of Proceeds					
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.					
		\$ 0	1	USD	<b>Estimate</b>
Clarification of Response (if Necessar	y)	_			
		1			

#### Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

#### **Terms of Submission**

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities
  described and undertaking to furnish them, upon written request, the information furnished to
  offerees
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Akers Biosciences, Inc.	/s/ Howard Yeaton	Howard Yeaton	Interim Chief Financial Officer	2020-04-14